Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-Aminopyridine for Diagnosing Recurrent Laryngeal Nerve Paralysis
NCT07832331Phase 1Not yet recruiting
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Dec 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, open-label, single-arm trial of dalfampridine in vocal cord paralysis and vocal cord paralysis (VCP), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Number of subjects with vocal cord paralysis at 3 hours. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
dalfampridine
03
Conditions
vocal cord paralysisvocal cord paralysis (VCP)
Beyond the preview
Go deeper on NCT07832331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832331.